OMERS ADMINISTRATION Corp Has $1.64 Million Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• OMERS ADMINISTRATION Corp has reduced its stake in Edwards Lifesciences by 83.1%, selling 110,846 shares during the first quarter, leaving them with 22,554 shares valued at approximately $1.6 million.
• Edwards Lifesciences reported a 72.96% net margin and a revenue of $1.53 billion, exceeding analyst estimates, with a year-over-year revenue increase of 11.9%.
• The company's stock has an average target price from analysts of $85.90, with ratings including three "Strong Buy" and twelve "Buy" ratings.

OMERS ADMINISTRATION Corp decreased its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 83.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 22,554 shares of the medical research company's stock after selling 110,846 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Edwards Lifesciences were worth $1,635,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. BNP Paribas Financial Markets boosted its position in shares of Edwards Lifesciences by 37.0% in the 1st quarter. BNP Paribas Financial Markets now owns 1,946,818 shares of the medical research company's stock valued at $141,105,000 after purchasing an additional 525,822 shares during the period. B. Metzler seel. Sohn & Co. AG boosted its position in shares of Edwards Lifesciences by 3.9% in the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 66,107 shares of the medical research company's stock valued at $4,791,000 after purchasing an additional 2,461 shares during the period. Ieq Capital LLC boosted its position in shares of Edwards Lifesciences by 50.2% in the 1st quarter. Ieq Capital LLC now owns 69,312 shares of the medical research company's stock valued at $5,024,000 after purchasing an additional 23,151 shares during the period. Epoch Investment Partners Inc. lifted its stake in Edwards Lifesciences by 15.4% in the 1st quarter. Epoch Investment Partners Inc. now owns 350,973 shares of the medical research company's stock worth $25,439,000 after acquiring an additional 46,772 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new stake in Edwards Lifesciences in the 1st quarter worth about $619,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.1%

Shares of EW traded down $0.07 during midday trading on Friday, reaching $80.89. 2,283,330 shares of the stock were exchanged, compared to its average volume of 3,558,037. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The firm has a 50 day simple moving average of $78.77 and a 200-day simple moving average of $75.21. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a market cap of $47.49 billion, a price-to-earnings ratio of 11.64, a P/E/G ratio of 3.90 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the business earned $0.70 EPS. The business's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,014 shares of company stock worth $1,698,844 over the last three months. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on EW shares. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Wall Street Zen raised Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Truist Financial increased their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Robert W. Baird increased their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Finally, JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.